Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis

World J Gastroenterol. 2010 May 7;16(17):2170-5. doi: 10.3748/wjg.v16.i17.2170.

Abstract

Aim: To investigate the association between peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene polymorphism 34 C>G and colorectal cancer (CRC), a meta-analysis review was performed in this report.

Methods: A systematic literature search and selection of eligible relevant studies were carried out. Nine independent studies with a total number of 4533 cases and 6483 controls were included in the meta-analysis on the association between polymorphism 34 C>G and CRC.

Results: There was no evidence for the association between PPAR-gamma 34 C>G and CRC if all of the subjects in the nine studies were included. However, CG + GG showed a marginally significant difference from CC (OR = 0.84, 95% CI: 0.69-1.01, P = 0.07) in random-effect model. Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk. No significant association was observed between PPAR-gamma 34 C>G and rectal cancer.

Conclusion: PPAR-gamma 34 C>G is associated with colon cancer risk, but not associated with CRC and rectal cancer risk.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Case-Control Studies
  • Colorectal Neoplasms / genetics*
  • Genetic Predisposition to Disease
  • Humans
  • Models, Genetic
  • PPAR gamma / genetics*
  • Polymorphism, Single Nucleotide
  • Risk Factors*

Substances

  • PPAR gamma